Related Experiment Video
Updated: Jul 16, 2026

In Vitro Model for Studying Differentiation and Changes of Multi-Omics on Murine Airway Epithelial Cells Stimulated with Cigarette Smoke Extract
Published on: July 12, 2024
Epigenomics in respiratory epithelium carcinogenesis: prevention and therapeutic challenges
Michalis V Karamouzis1, Panagiotis A Konstantinopoulos, Athanasios G Papavassiliou
1Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece.
Abstract:
Respiratory epithelium carcinogenesis is currently considered as the phenotypic aspect of serial genetic and epigenetic aberrations resulting in deregulation of cellular homeostasis. Recent data indicate that DNA demethylating agents and histone deacetylase inhibitors might act synergistically for the prevention of cancer development throughout the carcinogen-exposed epithelium. Preliminary clinical trials have shown encouraging results using these new molecules in lung carcinomas therapeutics. However, the caveats that should be overtaken for efficacious antitumour activity have also emerged. Setting the context in which epigenetic modifications contribute to carcinogenesis evolution is of paramount importance in order to optimize the potency of the current and future epigenome targeting agents.
Insights
Epigenetic modifications drive respiratory carcinogenesis. DNA demethylating agents and histone deacetylase inhibitors show promise in preventing and treating lung cancer by targeting these changes.
Area of Science:
- Oncology
- Epigenetics
- Respiratory Medicine
Background:
- Respiratory epithelium carcinogenesis involves genetic and epigenetic alterations that disrupt cellular balance.
- Epigenetic modifications play a crucial role in the progression of cancer in the respiratory tract.
Purpose of the Study:
- To explore the synergistic potential of DNA demethylating agents and histone deacetylase inhibitors in preventing respiratory carcinogenesis.
- To understand the role of epigenetic context in optimizing epigenome-targeting agents for cancer therapy.
Main Methods:
- Review of recent data on epigenetic modifications in respiratory carcinogenesis.
- Analysis of preliminary clinical trial results for DNA demethylating agents and histone deacetylase inhibitors in lung cancer therapeutics.
Main Results:
- DNA demethylating agents and histone deacetylase inhibitors show potential for synergistic cancer prevention in carcinogen-exposed epithelia.
- Early clinical trials indicate encouraging therapeutic outcomes for these agents in lung carcinomas.
- Challenges and caveats for achieving effective antitumor activity have been identified.
Conclusions:
- Optimizing epigenome-targeting agents requires a thorough understanding of how epigenetic modifications contribute to carcinogenesis.
- Further research is needed to overcome limitations and enhance the efficacy of these novel cancer therapies.
More Related Videos
08:42Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures
Published on: May 26, 2023
07:40Determining Ciliary Function and Membrane Impermeability of the Pseudostratified Lung Airway Epithelium
Published on: February 21, 2025
Related Concept Videos
Microbiota of the Respiratory Tract
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation